Drug intelligence / Profile preview

AD-Glc + Api

Development stage
Preclinical
Lead developer
ClichemBIO
Modality
Small Molecules, Nanoparticles → Drug Delivery Systems
Administration
Intravenous
01

Overview

AD-Glc + Api (also known as AD-Glc/Api) is a preclinical click-chemistry-based albumin nanocomplex developed as a theranostic platform for the treatment and imaging of idiopathic pulmonary fibrosis (IPF). The nanocomplex is synthesized by functionalizing native albumin with dibenzocyclooctyne (DBCO) to form AD, followed by the conjugation of azide-glucose via strain-promoted azide–alkyne cycloaddition (SPAAC) to yield glucose-functionalized albumin (AD-Glc). The active flavonoid apigenin (Api) is then loaded onto the AD-Glc carrier. The glucose ligand targets fibrotic lung tissue and inflammatory M1 macrophages by exploiting their upregulated glucose metabolism via glucose transporter 1 (GLUT1). Apigenin acts as the active therapeutic payload, exerting antifibrotic, anti-inflammatory, and antioxidant effects by scavenging reactive oxygen species (ROS) and inhibiting transforming growth factor-beta (TGF-β) signaling. In preclinical models of bleomycin-induced pulmonary fibrosis, AD-Glc/Api has demonstrated the ability to reduce inflammation, suppress epithelial-mesenchymal transition (EMT), inhibit fibroblast activation, and decrease collagen deposition, while also enabling non-invasive PET imaging tracking when radiolabeled.

Other names
albumin-dibenzycyclooctyne-glucose/apigeninapigenin-conjugated, glucose-modified albumin nanocomplexglucose-modified albumin nanocomplex
02

Identity

Drug type
Blood, Tissue and Cell-Derived Products
Modality
Small MoleculesNanoparticles
03

Pharmacology

04

Development

IndicationHighest phaseStatus
idiopathic pulmonary fibrosis (IPF)PreclinicalActive

Every indication, with countries and timelines, is in the full profile.

05

Regulatory

MarketStatusYear
United StatesNot approved—
European UnionNot approved—
ChinaNot approved—
JapanNot approved—

Approved indications and other markets are in the full profile.

06

Companies

  • ClichemBIOLead developer
07

Competitive landscape

Drugs on the same target
7
Drugs in the lead indication
217

Lead indication: idiopathic pulmonary fibrosis (IPF)

Most advanced in the lead indication

  1. fludeoxyglucose F18Approved
  2. nerandomilastApproved
  3. nintedanibApproved
  4. pirfenidoneApproved
  5. prednisoloneApproved

Beyond the preview

Go deeper on AD-Glc + Api.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on AD-Glc + Api.

Work on AD-Glc + Api? Claim this page to correct or add information. Claim this page

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call